Worldwide Market Reports added Latest Research Report titled “Global Orlistat Market by Manufacturers, Regions, Product Type and Application, Forecast up to 2026” to its Large Report database.
Orlistat is a drug that is used to treat obesity by preventing the absorption of fats from human diet. It acts as a lipase inhibitor to carry out this process and therefore, the caloric intake is reduced. This drug is usually used along with a healthcare provider-supervised reduced-calorie diet. Orlistat, a saturated derivative of lipstatin, was chosen for the development of an anti-obesity drug due to its simplicity and stability. The treatment using orlistat also helps in improving total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and insulin concentrations. Orlistat is available under various brand names, which include Orlean, Xenalten, Olistat, Alli, and Venustat.
Get PDF of Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/197230
Increasing disposable income that is promoting the consumption of fast foods and lack of exercise are factors that will increase the demand for drugs such as orlistat, thereby driving growth of the global orlistat market. Rising awareness of obesity and concern about being overweight are other factors that are expected to drive growth of the global orlistat market over the forecast period. Moreover, rising adoption of sedentary lifestyle, genetic factors, and increasing prevalence of chronic diseases also lead to obesity, in turn boosting growth of the market.
However, limited efficiency of currently available drugs and side effects caused by these drugs are major factors that hamper growth of the global orlistat market.
Key Developments in Orlistat Market
Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the orlistat market. On January 21, 2009, the European Medicines Agency granted approval for the sale of orlistat without a prescription.
On April 20, 2009, GlaxoSmithKline announced that alli (orlistat 60 mg), the first clinically proven over the counter weight loss aid, is available in the pharmacies across Europe.
Moreover, on January 23, 2006, the U.S. Food and Drug Administration (FDA) advisory panel voted 11 to 3 to recommend the approval of an OTC formulation of orlistat and the approval was granted on February 7, 2007.
Some of the major players operating in the global orlistat market include GlaxoSmithKline, Roche Holding AG, Aburaihan Pharmaceutical Co., and Taj Pharmaceuticals Limited among others.
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.
Worldwide Market Reports
Tel: +1 415 871 0703